Breast cancer vaccine trial begins enrolling people with BRCA1 and PALB2 mutations
https://www.facingourrisk.org/XRAY/breast-cancer-vaccine-BRCA1-PALB2
Full article: https://www.eventscribe.net/2022/SABCS/fsPopup.asp?Mode=PosterInfo&PosterID=533261
A new vaccine was first tested on people diagnosed with triple-negative breast cancer. The vaccine is now being tested to prevent breast cancer among people with an inherited mutation in BRCA1 or PALB2 who are at high risk and who are planning to have a risk-reducing mastectomy. (Posted 1/9/23) Este artículo está disponible en español.
Questions To Ask Your Health Care Provider
For people diagnosed with TNBC:
- Are any clinical trials of vaccines to treat breast cancer right for me?
- What is my stage of cancer?
- Am I considered at high risk for a recurrence of my cancer?
- Are any available targeted treatments, such as immunotherapies right for me?
For people who have never been diagnosed with breast cancer:
- Are any clinical trials of vaccines to prevent cancer right for me?
- Am I considered at high risk for triple-negative breast cancer?
- Are there any other medications I can take to lower my risk for breast cancer?
Open Clinical Trials
The following are breast cancer screening or prevention studies enrolling people at high risk for breast cancer.
- NCT04711109: Denosumab for Preventing Breast Cancer in Women with a BRCA1 Inherited Mutation (BRCA-P). This study will test the effectiveness of a drug (denosumab) in preventing the development of breast cancer in women with an inherited BRCA1 mutation.
- NCT04067726: Denosumab and Mammographic Density in Premenopausal Women With Dense Breasts (TRIDENT). This study is looking at the drug denosumab to learn if it can reduce breast density in high-risk premenopausal women who have dense breasts.
- The Risk Factor Analysis of Hereditary Breast and Ovarian Cancer In Women with BRCA1, BRCA2 or PALB2 Mutations. This study seeks to improve researchers’ understanding of how hormonal, reproductive and lifestyle factors may be associated with cancer in high-risk people.
- NCT02620852: Women Informed to Screen Depending on Measures of Risk (WISDOM) study. The goal of this study is to determine if breast cancer screening can be improved by personalizing each woman’s mammogram schedule, compared to the current one-size-fits-all annual approach.
-
NCT04674306: Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer. This study is testing a new vaccine to lower the risk of breast cancer in high-risk women with an inherited mutation in BRCA1, BRCA2 or PALB2.
Additional risk-management clinical trials for people at high risk for breast cancer may be found here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.